Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: TBPH theravance.com
Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of medicines for serious conditions. Its primary commercial asset is YUPELRI (revefenacin) inhalation solution, the first and only once-daily nebulized long-acting muscarinic antagonist (LAMA) bronchodilator approved in the U.S. for maintenance treatment of chronic obstructive pulmonary disease (COPD). YUPELRI is commercialized through a co-promotion arrangement with Viatris, under which Theravance receives a 35% share of net profits. The company also retains interests related to TRELEGY, a respiratory therapy marketed by GSK, through milestone payment arrangements with Royalty Pharma. Theravance is currently in the process of being acquired by Zymeworks Inc., with the transaction expected to close in the second half of 2026. The company has undergone a significant organizational restructuring following its Phase 3 CYPRESS clinical trial results, winding down its ampreloxetine development program and reducing operating costs substantially. Updated
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management. The billionaire is a value investor in the vein of Benjamin…
Wednesday's top analyst upgrades and downgrades included Beyond Meat, Boston Beer, Campbell Soup, Nordstrom, Okta, Owens Corning and Victoria’s Secret.
Theravance Biopharma is a biopharmaceutical company focused on the development and commercialization of medicines for serious conditions.
The Wall Street consensus 12-month price target for TBPH is $17.67.
